What is the Orum Therapeutics Inc. stock price forecast?

Orum Therapeutics Inc. is currently trading at ₩82,400. View real-time AI analysis on Alpha Lenz.

What is Orum Therapeutics Inc. insider trading activity?

View the latest insider trading data for Orum Therapeutics Inc. on Alpha Lenz.

What is Orum Therapeutics Inc.'s P/E ratio?

Orum Therapeutics Inc.'s P/E ratio is -194.3.

Orum Therapeutics Inc.

KRX · 475830

₩82,400

Ask about Orum Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Orum Therapeutics Inc. trades at a P/E of -194.3 (undervalued) with modest ROE of -4.7%.”

Ask for details →

Company Overview

Orum Therapeutics Inc. is a biopharmaceutical company specializing in the development of targeted protein degraders to treat diseases. The company's primary function is to create innovative therapeutics aimed at conditions for which current treatments are inadequate or non-existent. Utilizing its proprietary unique PROTAC technology, Orum Therapeutics focuses on selective degradation of disease-causing proteins, establishing a significant presence in the pharmaceutical and biotechnology industries. Headquartered in the vibrant biotech sector of Boston, Massachusetts, Orum Therapeutics Inc. plays an influential role in advancing scientific innovation and progress in medical treatment options. By addressing unmet medical needs, it contributes substantially to the portfolio of therapeutic advancements in the market aimed at improving patient care and outcomes globally.

CEO이승주

Websitehttps://www.orumrx.com

SectorHealthcare

IndustryBiotechnology

Employees20

Company Statistics

FY 2024

Profile

₩1,772,697,980,000Market Cap

₩20,905,620,570Revenue

21.51MShares Out

20Employees

Margins

100.00%Gross

-5.05%EBITDA

-39.87%Operating

-25.42%Pre-Tax

-27.46%Net

Valuation

-194.34P/E

9.16P/B

53.36EV/Sales

-1064.78EV/EBITDA

-88.92P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-3.73%ROA

-4.71%ROE

-2.29%ROIC

Financial Health

₩19,699,820,840Cash & Cash Equivalents

₩12,371,500,390Net Debt

26.34%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Orum Therapeutics Inc. trades at a P/E of -194.3 (undervalued) with modest ROE of -4.7%.”

Ask for details →

Frequently Asked Questions

Orum Therapeutics Inc. (ticker: 475830) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 20 employees. Market cap is $1.8T.

The current price is ₩82,400 with a P/E ratio of -194.34x and P/B of 9.16x.

ROE is -4.71% and operating margin is -39.87%. Annual revenue is $20.9B.